Bioxytran, Inc. (BIXT) Financial Statements (2026 and earlier)

Company Profile

Business Address C/O BIOXYTRAN, INC.
NEEDHAM, MA 02494
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments509,9145,15426,086295,40172,35841,688
Cash and cash equivalent509,9145,15426,086295,40172,35841,688
Prepaid expense 3,551    274,715
Total current assets:513,4655,15426,086295,40172,358316,403
Noncurrent Assets
Intangible asset, including goodwill, after accumulated amortization145,087133,540113,29675,53546,93210,000
Intangible asset, excluding goodwill, after accumulated amortization145,087133,540113,29675,53546,93210,000
Total noncurrent assets:145,087133,540113,29675,53546,93210,000
TOTAL ASSETS:658,552138,694139,382370,936119,290326,403
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:849,636278,258302,681749,395624,316348,127
Accounts payable      667
Accrued liabilities570,842353,841301,023748,405375,37184,325
Other undisclosed accounts payable and accrued liabilities278,794(75,583)1,658990248,945263,135
Debt855,000853,0001,900,0002,165,0002,122,1811,612,356
Deferred compensation liability    960  
Derivative instruments and hedges, liabilities403,353186,652    
Due to related parties✕✕✕✕709,727531,000307,176
Other undisclosed current liabilities1,141,905612,7321,041,55738,400  
Total current liabilities:3,249,8941,930,6423,244,2383,663,4823,277,4972,267,659
Noncurrent Liabilities
Total liabilities:3,249,8941,930,6423,244,2383,663,4823,277,4972,267,659
Equity
Equity, attributable to parent, including:(2,591,342)(1,791,948)(2,468,970)(2,701,918)(3,158,207)(1,941,256)
Preferred stock43,28443,158    
Common stock108,14886,783144,642123,252110,84197,451
Additional paid in capital18,301,47216,999,27913,085,7158,392,4305,881,8761,795,125
Accumulated deficit(21,044,246)(18,921,168)(15,699,327)(11,217,600)(8,753,668)(4,721,923)
Other undisclosed equity, attributable to parent     (397,256)888,091
Equity, attributable to noncontrolling interest   (680,886)(590,628)  
Other undisclosed equity   45,000   
Total equity:(2,591,342)(1,791,948)(3,104,856)(3,292,546)(3,158,207)(1,941,256)
TOTAL LIABILITIES AND EQUITY:658,552138,694139,382370,936119,290326,403

Income Statement (P&L) (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating expenses(1,842,509)(2,223,068)(3,800,212)(2,134,112)(4,214,434)(1,268,701)
Operating loss:(1,842,509)(2,223,068)(3,800,212)(2,134,112)(4,214,434)(1,268,701)
Nonoperating income (expense)(280,568)(156,937)(762,571)(523,192)(313,608)(1,273,826)
Interest and debt expense133,867(84,240)  (236,577)(1,014,769)
Other undisclosed income from continuing operations before equity method investments, income taxes     236,5771,014,769
Loss from continuing operations before equity method investments, income taxes:(1,989,210)(2,464,245)(4,562,783)(2,657,304)(4,528,042)(2,542,527)
Other undisclosed income (loss) from continuing operations before income taxes(133,867)84,240    
Loss from continuing operations:(2,123,077)(2,380,005)(4,562,783)(2,657,304)(4,528,042)(2,542,527)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(4,528,042)(2,542,527)
Other undisclosed net income     496,29761,909
Net loss:(2,123,077)(2,380,005)(4,562,783)(2,657,304)(4,031,745)(2,480,618)
Net income attributable to noncontrolling interest  13,32490,258193,372496,29761,909
Other undisclosed net loss attributable to parent     (992,594)(123,818)
Net loss attributable to parent:(2,123,077)(2,366,681)(4,472,525)(2,463,932)(4,528,042)(2,542,527)
Other undisclosed net income available to common stockholders, basic     496,297 
Net loss available to common stockholders, diluted:(2,123,077)(2,366,681)(4,472,525)(2,463,932)(4,031,745)(2,542,527)

Comprehensive Income (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(2,123,077)(2,380,005)(4,562,783)(2,657,304)(4,031,745)(2,480,618)
Comprehensive loss:(2,123,077)(2,380,005)(4,562,783)(2,657,304)(4,031,745)(2,480,618)
Comprehensive income, net of tax, attributable to noncontrolling interest  13,32490,258193,372496,29761,909
Comprehensive loss, net of tax, attributable to parent:(2,123,077)(2,366,681)(4,472,525)(2,463,932)(3,535,448)(2,418,709)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: